

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA214; Bevacizumab in combination with a taxane for the first line treatment of metastatic breast cancer

This guidance was issued February 2011 with a review date of July 2013.

Background

At the GE meeting of 16 July 2013 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	TA214 should be transferred to the 'static' guidance list.
Rationale for selecting this proposal	<p>A systematic review published in 2012 (Wagner et al.) found only one additional study that was not included in the original appraisal. This study was a randomised double-blind, assessing the efficacy of another investigational anti-VEGF drug, motesanib placebo-controlled trial versus placebo and open-label bevacizumab (Martin et al., 2011). In an accompanying editorial, it was noted that "weekly paclitaxel resulted in a higher response rate and longer control of disease than was noted in the E2100 clinical trial; and the addition of bevacizumab did not significantly improve response rates or progression-free survival" (Buzdar, 2011). The results of the meta-analysis including this study would not change the Committee's original conclusion that bevacizumab may improve progression-free survival relative to taxanes alone, but that there is no robust evidence that bevacizumab improves overall survival.</p> <p>A randomised, double-blind, placebo-controlled, study to evaluate the efficacy and safety of bevacizumab, and associated biomarkers, in combination with paclitaxel compared with paclitaxel plus placebo as first-line treatment of HER2-negative metastatic breast cancer is not expected to complete until the end of 2018.</p>

	Given that there is no new evidence to suggest that the guidance should change, it is proposed that this guidance moves to the static list.
--	---

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	TA214 will be transferred to the 'static' guidance list.
--	--

Respondent	Response to proposal	Details	Comment from Technology Appraisals
National Cancer Research Institute / Royal College of Physicians / Royal College of Radiologists / Association of Cancer Physicians	Agree	The NCRI/RCP/RCR/ACP/JCCO supports NICE's proposal to move TA214 to the static list. We are not aware of any new data or evidence at this time.	Response noted.

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Royal College of Nursing	No Comments	This is just to let you know that the feedback I have received from nurses working in this area of health suggest that there are no comments to submit on behalf of the Royal College of Nursing to inform on the review proposal of the technology.	Response noted.
Roche Products	Agree	We are still not aware of any new evidence to suggest the existing above mentioned guidance should change, and therefore agree for the time being that TA214 should be moved to the static list.	Response noted.

No response received from:

<u>Patient/carer groups</u>	<u>General</u>
<ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • Breakthrough Breast Cancer • Breast Cancer Campaign • Breast Cancer Care • Breast Cancer UK • Cancer Black Care • Cancer Equality • Equalities National Council • Haven • Helen Rollason Cancer Charity • Independent Age • Independent Cancer Patients Voice 	<ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit

- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie Cancer Care
- Muslim Council of Britain
- Muslim Health Network
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus
- Women's Health Concern

Professional groups

- British Association for Services to the Elderly
- British Geriatrics Society
- British Institute of Radiology
- British Psychosocial Oncology Society
- Cancer Network Pharmacists Forum
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Pathologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

Others

- Department of Health
- NHS England
- NHS Kernow CCG
- NHS West Kent CCG

- NHS Confederation
- Scottish Medicines Consortium

Comparator manufacturers

- Accord Healthcare (docetaxel, gemcitabine and paclitaxel)
- Actavis UK (docetaxel, gemcitabine and paclitaxel)
- Bristol-Myers-Squibb (paclitaxel)
- Fresenius Kabi Oncology (gemcitabine and paclitaxel)
- Hospira UK (paclitaxel)
- Lilly UK (gemcitabine)
- Medac GmbH UK (docetaxel, gemcitabine and paclitaxel)
- Mylan UK (gemcitabine)
- Sandoz (docetaxel, gemcitabine and paclitaxel)
- Sanofi (docetaxel)
- Sun Pharmaceuticals (gemcitabine)
- Teva UK (docetaxel, gemcitabine and paclitaxel)
- Wockhardt (gemcitabine and paclitaxel)

Relevant research groups

- Against Breast Cancer
- Breast Cancer Hope
- Breast Cancer Research Trust
- Cochrane Breast Cancer Group
- Health Research Authority
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Network
- National Institute for Health Research
- Pro-Cancer Research Fund
- Research Institute for the Care of Older People

<ul style="list-style-type: none"> • Welsh Government 	<p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Assessment Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust
--	--

GE paper sign-off: Janet Robertson, Associate Director – Technology Appraisals Programme

Contributors to this paper:

Technical Lead: Ahmed Elsada

Project Manager: Andrew Kenyon

23 August 2013